Articles tagged with: Revlimid
Novel agents, such as Velcade (bortezomib) and Revlimid (lenalidomide), have greatly advanced the treatment of patients with multiple myeloma. Indeed, by incorporating novel agents as induction therapy prior to consolidation with high-dose therapy and autologous stem cell transplantation, we have made huge strides in survival outcomes over the last 10 years. However, treatment with anti-myeloma agents may be associated with side effects that negatively impact quality of life.
Recently, two advances have been reported resulting in a decrease in peripheral neuropathy (nerve damage causing pain, numbness, and/or tingling …
The results of a recent Phase 2 trial show that the addition of cyclophosphamide to Revlimid and low-dose dexamethasone may result in better responses for previously untreated myeloma patients.
“This [study] provides the efficacy of another regimen for use in patients with myeloma,” said the study’s lead author Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minnesota. “It is a fairly safe combination and is quite efficacious,” he stated in an e-mail to The Myeloma Beacon.
Italian researchers recently found that most myeloma patients are able to collect sufficient stem cells after a short course of induction therapy with Revlimid, allowing them to undergo two consecutive stem cell transplants.
“Revlimid can be used safely before stem cell mobilization, provided that we use only four courses before mobilization and cyclophosphamide is used to mobilize,” said Dr. Antonio Palumbo, lead author of the study and a researcher at the University of Torino in Italy.
The current standard treatment for younger patients with newly diagnosed myeloma includes induction therapy …
As the myeloma community continues to investigate whether stem cell transplantation or novel agents is the best way to treat newly diagnosed myeloma patients, recent results from a Phase 3 clinical trial indicate that stem cell transplantation may lead to longer disease-free survival.
The results from this study show that more multiple myeloma patients who received a stem cell transplant were alive and disease-free after 24 months compared to patients treated with Revlimid in combination with conventional chemotherapy.
The transplanted patients, however, also experienced more severe side effects compared to …
Results of a Phase 2 clinical trial show that elotuzumab in combination with Revlimid and low-dose dexamethasone is safe and effective in relapsed/refractory multiple myeloma patients.
“Elotuzumab in combination with Revlimid and low-dose dexamethasone has a very high response rate,” said Dr. Philippe Moreau from the University Hospital in Nantes, France, when he presented the findings at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.
“[The combination] seems to be superior to Revlimid plus high-dose dexamethasone,” he added.
In a summary talk about potential …